

#### School of Public Health Athena SWAN Lecture 2013



#### What women can do to stay healthy

Professor Dame Valerie Beral DBE AC FRS, Professor of Epidemiology, University of Oxford





#### Charter for women in science


Recognising commitment to advancing women's careers in STEMM academia

### What women can do to stay healthy

Valerie Beral
University of Oxford







# Disease rates vary by age; and exposures vary by age

#### **Questions:**

What are the effects of important potentially modifiable exposures?

Are the effects persistent?

#### **Exposures:**

The pill; HRT; adiposity; physical activity; alcohol and diet; smoking

#### THE PILL

- First licensed in ~1960
- 600 million women have used it
- 120 million are currently using it

### In western countries today:

- women in their 60s, 80% ever-users (for 7 years)
- women in their 90s, 30% ever-users (for 5 years)

#### THE PILL

#### 1960 and 1970s – adverse vascular effects

- 1961 first report of venous thrombosis (VTE)
- 1962 26 cases of VTE reported to FDA
- 1962 first report of stroke
- 1964 first report of coronary heart disease

2-4 fold increase in venous thromboembolism, stroke and heart disease

#### All vascular effects are reversible


### 1980s and 1990s-emphasis on cancer

- 1980s over 30 studies published results on breast cancer and the pill, with conflicting findings
- 1992 Collaborative Group on Hormonal Factors in Breast Cancer set up in Oxford to bring together worldwide data; first results published in 1996




#### Oral contraceptives and breast cancer incidence


Collaborative Group on Hormonal Factors in Breast Cancer (Lancet, 1996)




#### Excess breast cancer risk is reversible


## Persistent reduction in ovarian and endometrial cancer risk – greater the longer the pill was used







## Persistent reduction in ovarian and endometrial cancer risk – greater the longer the pill was used





A decade or so after stopping the pill the net effect is a reduction cancer incidence and mortality







- 1.3 million women recruited in 1996-2001, from NHS Breast Screening Units
- to obtain reliable evidence about breast cancer and women's health in general
- 1 in 4 UK women aged 50-64 at the time of recruitment
- average age 56 at recruitment, now 70



# HRT and cancer incidence



HRT and cancer incidence



MHRA, advice since 2002: use HRT for as short a time as possible

#### Type of HRT and risk of breast cancer


HRT type currently used	BREAST CANCER Relative risk (95% CI)			
Transdermal oestrogen only	1.24	-		
Oral oestrogen only	1.32	=		
Oral oestrogen plus progestagen	2.00			
	_	1.0	2.0	

#### HRT type and risk of various conditions

HRT type currently used		EAST CA ive risk (		GALLBLADDER DISEASE Relative risk (95% CI)		VENOUS THROMBOEMBOLISM Relative risk (95% CI)			
Transdermal oestrogen only	1.24	-		1.17			0.82 -	-	
Oral oestrogen only	1.32			1.81			1.42	-	_
Oral oestrogen plus progestagen	2.00			1.69			2.07		-
	_	1.0	2.0	_	1.0	2.0	_	1.0	2.0

#### Coronary heart disease: results from randomized trials\*

#### little or no increase or difference by type of HRT




#### \*MHRA Public Assessment Report, 2007 (www.mhra.gov.uk)


However, as yet there is no evidence to support a cardioprotective effect of HRT, and further research is needed before any firm conclusions can be drawn about the effect of HRT on CHD in younger women.

#### Stroke: results from randomised trials\*


#### increased incidence with HRT use




<sup>\*</sup>MHRA Public Assessment Report, 2007 (www.mhra.gov.uk)



Drop in HRT use has been followed by a fall in breast cancer incidence in a dozen countries




Ravdin, NEJM, 2007




### **OBESITY**

Persistent effect of childbearing on body mass index in postmenopausal women




## Breastfeeding and breast cancer risk: persistent protection throughout life




Collaborative Group on Hormonal Factors in Breast Cancer, Lancet 2002


## Circulating levels of oestrogen by body mass index in postmenopausal women




Obesity and endometrial cancer risk in



#### Obesity and endometrial cancer risk




# BODY MASS INDEX and hospital admissions



### Physical activity


## PHYSICAL ACTIVITY and fracture risk



#### PHYSICAL ACTIVITY

Dementia risk in inactive versus active


"Reverse causation"
- early dementia
causes inactivity




### **ALCOHOL** and **DIET**

**CIRRHOSIS:** 

ALCOHOL & OBESITY




# ALCOHOL and cancer incidence



Type of alcohol and breast cancer risk











Crowe et al

### **SMOKING**


All cause mortality in smokers



# Lung cancer histology in smokers



All cause mortality in ex-smokers



### What will definitely improve health:

- Don't smoke; give up if you do
- Keep your weight down
- Breastfeed, if you have children
- Exercise, but possibly not too much
- Drink as little alcohol as possible (until old age)
- Eat fruits and vegetables
- Take the pill, but stop before ~age 40 years
- Take menopausal hormones as little as possible

MANY EFFECTS ARE REVERSIBLE so it is rarely too late to benefit from a change

Benefits from each can be small, BUT TOGETHER CAN BE LARGE

